Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 5/20 | 0.50 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | YAP1 | P46937 | 3/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27380373 | 1.00 | PRMT5 (0.50) | PRMT5STSYAP1GPR119GAA | |
| SCHEMBL10196271 | 0.89 | PRMT5 (0.52) | PRMT5STSYAP1GPR119GAA | |
| SCHEMBL27380422 | 0.87 | GPR119 (0.46) | PRMT5GPR119KDM4EPKMWDR77 | |
| SCHEMBL30812300 | 0.87 | GPR119 (0.46) | PRMT5GPR119KDM4EPKMWDR77 | |
| SCHEMBL27390005 | 0.86 | YAP1 (0.53) | PRMT5STSYAP1GPR119KDM4E | |
| SCHEMBL30812286 | 0.86 | YAP1 (0.47) | PRMT5STSYAP1GPR119ACHE | |
| SCHEMBL21458596 | 0.84 | STS (0.53) | PRMT5STSYAP1GPR119GAA | |
| SCHEMBL24320673 | 0.84 | PRMT5 (0.60) | PRMT5STSYAP1GPR119GAA | |
| SCHEMBL30824771 | 0.83 | YAP1 (0.51) | PRMT5STSYAP1GPR119KDM4E | |
| SCHEMBL30824815 | 0.83 | YAP1 (0.51) | PRMT5STSYAP1GPR119KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388605-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO INC (US) | 2025-12-25 | — | — | US | disclosed |
| WO-2024054956-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388605-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | BRD4, BRDT, BICRA | PRMT5 586/4885STS 4121/4885YAP1 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.